Business
Esperion Announces Closing of $225 Million Public Offering
ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"ANN ARBOR, Mich., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the closing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and accompanying warrants to purchase an aggregate of up to 32,142,858 shares of common stock for gross proceeds of approximately $225 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of its common stock and/or additional warrants to purchase up to 4,821,428 shares of its common stock, which the underwriter has partially exercised for warrants to purchase 4,821,428 shares of common stock. At closing, Esperion received net proceeds from the offering of approximately $208.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. All of the securities sold in the offering were offered by Esperion. Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes. H.C. Wainwright & Co. acted as sole book-running manager for the public offering. The offering was made only by means of a written prospectus and related prospectus supplement forming part of Esperion’s shelf registration statement on Form S‑3ASR (File No. 333-258397) that was previously filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2021, and which became effective upon filing. The final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at [email protected]. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or o...